Biocartis Group NV
BIOCARTIS LAUNCHES EQUITY PLACEMENT
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW
PRESS RELEASE: REGULATED INFORMATION - INSIDE INFORMATION
23 January 2019, 14:00 CET
BIOCARTIS LAUNCHES EQUITY PLACEMENT
Mechelen, Belgium, 23 January 2019 - Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today the launch of an equity offering to raise an amount of approximately EUR 45 million by means of a private placement via an accelerated bookbuild offering (the "Offering").
Biocartis currently envisages using the net proceeds to fund the expansion of the Idylla(TM) test menu and applications, its sales and marketing activities, further investments in its cartridge
manufacturing capacity, and for working capital and other general corporate purposes.
The accelerated bookbuilding procedure will commence immediately. The Company will announce the results of the Offering as soon as possible after closing of the bookbuilding in a subsequent press
release.
Trading in Biocartis shares on Euronext Brussels will be suspended during the bookbuilding period. Trading in the stock is expected to resume following the publication of the results of the
Offering.
Joh. Berenberg, Gossler & Co. KG ("Berenberg"), KBC Securities SA/NV ("KBC Securities") and Kempen & Co N.V. ("Kempen") are acting as Joint Bookrunners in the
Offering.
In relation to the Offering, the Company has agreed with the Joint Bookrunners to a market customary 90 days standstill period on future share issuances, waivable by the Joint Bookrunners subject
to customary exceptions.
--- END ---
More information:
Renate Degrave
Manager Corporate Communications & Investor Relations
e-mail rdegrave@biocartis.com
tel +32 15 631 729
mobile +32 471 53 60 64
About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of
patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers
accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a rapidly expanding test menu addressing key
unmet clinical needs in oncology. This area represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More
information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.